100 related articles for article (PubMed ID: 21098201)
1. 18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique.
Osman MM; Chaar BT; Muzaffar R; Oliver D; Reimers HJ; Walz B; Nguyen NC
AJR Am J Roentgenol; 2010 Dec; 195(6):1397-403. PubMed ID: 21098201
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
3. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis.
Sebro R; Mari-Aparici C; Hernandez-Pampaloni M
Acta Radiol; 2013 Jun; 54(5):534-9. PubMed ID: 23463863
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma.
Niederkohr RD; Rosenberg J; Shabo G; Quon A
Nucl Med Commun; 2007 Sep; 28(9):688-95. PubMed ID: 17667747
[TBL] [Abstract][Full Text] [Related]
5. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
Querellou S; Keromnes N; Abgral R; Sassolas B; Le Roux PY; Cavarec MB; Le Duc-Pennec A; Couturier O; Salaun PY
Nucl Med Commun; 2010 Sep; 31(9):766-72. PubMed ID: 20585271
[TBL] [Abstract][Full Text] [Related]
6. Role of limited whole-body PET/CT in pediatric lymphoma.
Sammer MB; Shulkin BL; Alessio A; Parisi MT
AJR Am J Roentgenol; 2011 May; 196(5):1047-55. PubMed ID: 21512070
[TBL] [Abstract][Full Text] [Related]
7. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
Kumar R; Hawkins RA; Yeh BM; Wang ZJ
Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
[TBL] [Abstract][Full Text] [Related]
8. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG-avid plantar nodules on true whole-body 18F-FDG PET/CT in cancer patients.
Muzaffar R; Raslan O; Osman MM
Nucl Med Commun; 2015 Sep; 36(9):881-6. PubMed ID: 25932543
[TBL] [Abstract][Full Text] [Related]
10. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern.
Chowdhury FU; Sheerin F; Bradley KM; Gleeson FV
Clin Radiol; 2009 Jul; 64(7):675-81. PubMed ID: 19520211
[TBL] [Abstract][Full Text] [Related]
11. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
12. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and patterns of soft tissue metastasis: detection with true whole-body F-18 FDG PET/CT.
Nguyen NC; Chaar BT; Osman MM
BMC Med Imaging; 2007 Dec; 7():8. PubMed ID: 18076764
[TBL] [Abstract][Full Text] [Related]
14. Whole-body 18F FDG positron emission tomography/computed tomography evaluation of patients with uveal metastasis.
Patel P; Finger PT
Am J Ophthalmol; 2012 Apr; 153(4):661-8. PubMed ID: 22264690
[TBL] [Abstract][Full Text] [Related]
15. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
[TBL] [Abstract][Full Text] [Related]
16. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors.
Bochev P; Klisarova A; Kaprelyan A; Chaushev B; Dancheva Z
Hell J Nucl Med; 2012; 15(2):125-9. PubMed ID: 22741148
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies.
Tatsumi M; Miller JH; Wahl RL
J Nucl Med; 2007 Dec; 48(12):1923-31. PubMed ID: 18056332
[TBL] [Abstract][Full Text] [Related]
18. Frequency and clinical implications of incidental new primary cancers detected on true whole-body 18F-FDG PET/CT studies.
Sebro R; Aparici CM; Pampaloni MH
Nucl Med Commun; 2013 Apr; 34(4):333-9. PubMed ID: 23407371
[TBL] [Abstract][Full Text] [Related]
19. Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma?
Tan JC; Chatterton BE
Hell J Nucl Med; 2012; 15(3):202-5. PubMed ID: 23106051
[TBL] [Abstract][Full Text] [Related]
20. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
